

PRESENTED ABSTRACTS & SESSIONS

Saturday, June 4, 2011

8:00 a.m. - 12:00 p.m.

General Poster Session: 

Gastrointestinal (Colorectal) Cancer

Poster No: 12D

Abstract No: 3556

Presenter:

Qian Shi, PhD

Location: South Building,  
Level 3 Hall A

[http://abstract.asco.org/  
AbstView\\_102\\_84534.htm](http://abstract.asco.org/AbstView_102_84534.htm)

Lymph node ratio risk classification in stage III colon cancer: A pooled analysis of 16,425 patients from the ACCENT database.

8:00 a.m. - 12:00 p.m.

General Poster Session: 

Gastrointestinal (Colorectal) Cancer

Poster No: 19H

Abstract No: 3616

Presenter:

Judy-Anne W. Chapman,  
PhD

Location: South Building,  
Level 3 Hall A

[http://abstract.asco.org/  
AbstView\\_102\\_78884.html](http://abstract.asco.org/AbstView_102_78884.html)

Comparison of innovative estimation of efficacy to standard using the ACCENT database.

8:00 a.m. - 12:00 p.m.

General Poster Session: 

Gastrointestinal (Colorectal) Cancer

Poster No: 20C

Abstract No: 3619

Presenter:

Winson Y. Cheung, MD,  
MPH

Location: South Building,  
Level 3 Hall A

[http://abstract.asco.org/  
AbstView\\_102\\_79417.html](http://abstract.asco.org/AbstView_102_79417.html)


Predictive and prognostic value of gender in early stage colon cancer: A pooled analysis of 33,345 patients from the ACCENT database.

Saturday, June 4, 2011

1:00 p.m. - 1:15 p.m.

Best of ASCO Selection

Oral Abstract

Presentation Session: 

Gastrointestinal (Colorectal) Cancer

Abstract No: 3503

Presenter:

Mark S. Roh, MD

Location: Lakeside Center,  
Level 3 Hall D1


[http://abstract.asco.org/  
AbstView\\_102\\_76910.html](http://abstract.asco.org/AbstView_102_76910.html)

The impact of capecitabine and oxaliplatin in the preoperative multimodality treatment in patients with carcinoma of the rectum: NSABP R-04.

2:15 p.m. - 2:30 p.m.

Best of ASCO Selection

Oral Abstract

Presentation Session: 

Gastrointestinal (Colorectal) Cancer

Abstract No: 3507

Presenter:

Gregory A. Yothers, PhD

Location: Lakeside Center,  
Level 3 Hall D1

[http://abstract.asco.org/  
AbstView\\_102\\_82093.html](http://abstract.asco.org/AbstView_102_82093.html)

The efficacy of oxaliplatin when added to 5-fluorouracil/leucovorin in stage II colon cancer.

2:30 p.m. - 2:45 p.m.

Oral Abstract

Presentation Session: 

Gastrointestinal (Colorectal) Cancer

Abstract No: 3508

Presenter:

Carmen J Allegra, MD

Location: Lakeside Center,  
Level 3 Hall D1


[http://abstract.asco.org/  
AbstView\\_102\\_78086.html](http://abstract.asco.org/AbstView_102_78086.html)

Overall survival and updated disease-free survival results of the NSABP C-08 trial assessing bevacizumab in stage II and III colon cancer

PRESENTED ABSTRACTS & SESSIONS

Saturday, June 4, 2011

2:00 p.m. - 6:00 p.m.

**Poster Discussion Session:**  *Breast Cancer - Triple-negative/Cytotoxics/Local Therapy*

**Poster No:** 1  
**Abstract No:** 1011

**Presenter:**  
Thomas B. Julian, MD


**Location:**  
Display: Lakeside Center  
Level 4 E450b,

Discussion:  
5:00 p.m. - 6:00 p.m.  
North Building,  
Level 2 Hall B1

[http://abstract.asco.org/AbstView\\_102\\_83615.html](http://abstract.asco.org/AbstView_102_83615.html)

Early toxicity results with 3-D conformal external beam therapy from the NSABP B-39/RTOG 0413 accelerated partial breast irradiation trial.

2:00 p.m. - 6:00 p.m.

**Poster Discussion Session:**  *Breast Cancer - Triple-negative/Cytotoxics/Local Therapy*

**Poster No:** 19  
**Abstract No:** 1029

**Lead Author:**  
Kui Shen, PhD

**Presenter:**  
Nan Song, PhD

**Location:**  
Display: Lakeside Center,  
Level 4 E450b

Discussion:  
5:00 p.m. - 6:00 p.m.  
North Building,  
Level 2 Hall B1

[http://abstract.asco.org/AbstView\\_102\\_80460.html](http://abstract.asco.org/AbstView_102_80460.html)

Multigene predictors developed on breast cancer cell lines to predict patient chemotherapy response: A validation study on the NSABP B-27 trial.

Monday, June 6, 2011

8:00 a.m. - 12:00 p.m.

**General Poster Session:**  *Tumor Biology*

**Poster No:** 30B  
**Abstract No:** 10590

**Presenter:**  
Nathan R. Foster, MS

**Location:** South Building,  
Level 3 Hall A

[http://abstract.asco.org/AbstView\\_102\\_82287.html](http://abstract.asco.org/AbstView_102_82287.html)

Body mass index and DNA mismatch repair status in colon cancers from patients treated in adjuvant therapy trials.

8:00 a.m. - 12:00 p.m.

**Trials in Progress Poster Session:**  *Clinical Trials*

**Poster No:** 36E  
**Abstract No:** TPS103


**Presenter:**  
Wendy Parulekar, MD

**Location:** South Building,  
Level 3, Hall A

[http://abstract.asco.org/AbstView\\_102\\_82573.html](http://abstract.asco.org/AbstView_102_82573.html)

A phase III randomized trial of metformin versus placebo on recurrence and survival in early stage breast cancer (NCIC Clinical Trials Group MA.32).

8:00 a.m. - 12:00 p.m.

**Poster Discussion Session:**  *Cancer Prevention/Epidemiology*

**Poster No:** 20  
**Abstract No:** 1528

**Presenter:**  
Eitan Amir, MB, ChB

**Location:**  
Display: South Building,  
Level 1 S102

Discussion:  
11:30 a.m. - 12:30 p.m.  
South Building,  
Grand Ballroom 100a


[http://abstract.asco.org/AbstView\\_102\\_76755.html](http://abstract.asco.org/AbstView_102_76755.html)

25-hydroxy vitamin D and associated variables as predictors of breast cancer risk and tamoxifen benefit in NSABP P-1.

PRESENTED ABSTRACTS & SESSIONS

Monday, June 6, 2011

10:15 a.m. - 10:45 a.m.  
**Best of ASCO Selection**

**Oral Abstract Presentation Session:**   
*Breast Cancer - Triple-negative/Cytotoxics/Local Therapy*

**Abstract No:** LBA1005


**Presenter:**  
*Harry D. Bear, MD, PhD*

**Location:** North Building,  
Level 3 Hall B1

[http://abstract.asco.org/AbstView\\_102\\_83942.html](http://abstract.asco.org/AbstView_102_83942.html)

The effect on pCR of bevacizumab and/or antimetabolites added to standard neoadjuvant chemotherapy: NSABP protocol B-40.

1:00 p.m. - 5:00 p.m.

**General Poster Session:**   
*Breast Cancer – HER2/ER*

**Poster No:** 7F  
**Abstract No:** 588


**Presenter:**  
*Kalliopi P. Siziopikou, MD*

**Location:** South Building,  
Level 3 Hall A

[http://abstract.asco.org/AbstView\\_102\\_84489.html](http://abstract.asco.org/AbstView_102_84489.html)

Preliminary results of centralized HER2 testing in DCIS of the breast: NSABP B-43.

1:00 p.m. - 5:00 p.m.

**General Poster Session:**   
*Breast Cancer – HER2/ER*

**Poster No:** 8B  
**Abstract No:** 592

**Presenter:**  
*Michael Crager, PhD*


**Location:** South Building,  
Level 3 Hall A

[http://abstract.asco.org/AbstView\\_102\\_78110.html](http://abstract.asco.org/AbstView_102_78110.html)

Using the 21-Gene Recurrence Score and the recently developed Recurrence Score-Pathologic-Clinical to assess recurrence risk in patients with node-negative, ER-positive early-stage breast cancer receiving aromatase inhibitor treatment alone.

Monday, June 6, 2011

4:30 p.m. - 4:45 p.m.

**Oral Abstract Presentation Session:**   
*Cancer Prevention/Epidemiology*

**Abstract No:** 1505

**Presenter:**  
*Stephanie R. Land, PhD*

**Location:**  
*South Building, Level 1,  
Grand Ballroom S100bc*

[http://abstract.asco.org/AbstView\\_102\\_83894.html](http://abstract.asco.org/AbstView_102_83894.html)

Cigarette smoking, fitness, and alcohol use as predictors of cancer outcomes among women in the National Surgical Adjuvant Breast and Bowel Project (NSABP) Breast Cancer Prevention Trial (BCPT).

ASCO Electronic Publication-Only Abstract

*A full-text version of the publish-only abstract will appear on [www.asco.org](http://www.asco.org) and [www.jco.org](http://www.jco.org) beginning May 18, 2011. It will not be presented during the meeting.*

**Publish-Only Abstract:**

**Abstract No:** e21126

**Lead Author:**  
*Frank A. Sinicrope, MD*

**NSABP Author:**  
*Gregory A. Yothers, PhD*

[http://abstract.asco.org/AbstView\\_102\\_83516.html](http://abstract.asco.org/AbstView_102_83516.html)

Body mass index as a prognostic and predictive factor in stage II/III colon cancer – an analysis of the ACCENT database.